Teach-back: An underutilized toolIn an effort to encourage nurses to use the teach-back method when educating patients, we conducted a literature review on the topic of patient…
Repetitive transcranial magnetic stimulation may improve memoryAccording to a study in PLoS ONE, repetitive transcranial magnetic stimulation improves memory. (more…)
Healthcare professionals’ implementation of EBP laggingAlthough healthcare professionals’ self‐reported evidence-based practice (EBP) knowledge, skills, attitudes, and beliefs are at a moderate to high level, this doesn’t translate into EBP…
Prescription drugs in pregnant and nursing womenOn May 8, the FDA released two draft guidance documents designed to improve understanding of effects of prescription drugs in pregnant and nursing women.…
FDA approves treatment for two rare diseasesOn May 6, the FDA approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome in patients 6 to less than 17 years…
Healthcare professionals and medicinal cannabisAccording to a systematic review in PLOSOne, healthcare professionals generally support the use of medicinal cannabis, but they lack knowledge and are concerned about…
ANA on the Frontline, May 2019Learn about the top issues facing ANA member nurses, how ANA is working for you, and what ANA is doing to advance nursing. In…
May 2019 Vol. 14 No. 5This issue includes two articles with so much information that we had to break them into two parts. The first is a feature titled…
FDA approves first treatment for pediatric patients with lupusOn April 26, the FDA approved Benlysta (belimumab) I.V. infusion for treatment of children with systemic lupus erythematosus (SLE). This is the first FDA-approved…
FDA approves treatment for hepatitis C in childrenOn April 30, the FDA approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages…
FDA approves medical device for ADHDOn April 19, the FDA permitted marking of the first medical device to treat attention deficit hyperactivity disorder (ADHD): Monarch external Trigeminal Nerve Stimulation…
FDA approves generic naloxone nasal sprayOn April 19, the FDA approved the first generic naloxone hydrochloride nasal spray (Narcan). (more…)
Teach-back: An underutilized toolIn an effort to encourage nurses to use the teach-back method when educating patients, we conducted a literature review on the topic…
Repetitive transcranial magnetic stimulation may improve memoryAccording to a study in PLoS ONE, repetitive transcranial magnetic stimulation improves memory. (more…)
Healthcare professionals’ implementation of EBP laggingAlthough healthcare professionals’ self‐reported evidence-based practice (EBP) knowledge, skills, attitudes, and beliefs are at a moderate to high level, this doesn’t translate…
Prescription drugs in pregnant and nursing womenOn May 8, the FDA released two draft guidance documents designed to improve understanding of effects of prescription drugs in pregnant and…
FDA approves treatment for two rare diseasesOn May 6, the FDA approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome in patients 6 to less than…
Healthcare professionals and medicinal cannabisAccording to a systematic review in PLOSOne, healthcare professionals generally support the use of medicinal cannabis, but they lack knowledge and are…
ANA on the Frontline, May 2019Learn about the top issues facing ANA member nurses, how ANA is working for you, and what ANA is doing to advance…
May 2019 Vol. 14 No. 5This issue includes two articles with so much information that we had to break them into two parts. The first is a…
FDA approves first treatment for pediatric patients with lupusOn April 26, the FDA approved Benlysta (belimumab) I.V. infusion for treatment of children with systemic lupus erythematosus (SLE). This is the…
FDA approves treatment for hepatitis C in childrenOn April 30, the FDA approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in…
FDA approves medical device for ADHDOn April 19, the FDA permitted marking of the first medical device to treat attention deficit hyperactivity disorder (ADHD): Monarch external Trigeminal…
FDA approves generic naloxone nasal sprayOn April 19, the FDA approved the first generic naloxone hydrochloride nasal spray (Narcan). (more…)
Teach-back: An underutilized toolBy: Donna L. Denault MSN, BSN, RN; Sarah M. Wilcox MSN, BS, RN; Karen Breda, PhD, RN; Karen V. Duhamel, DNP, MSHCE, RN; and Susan Eichar, EdD, APRN
